IOVA
Income statement / Annual
Last year (2023), Iovance Biotherapeutics, Inc.'s total revenue was $1.19 M,
and the percentage change from the previous year is not available.
In 2023, Iovance Biotherapeutics, Inc.'s net income was -$444.04 M.
See Iovance Biotherapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$1.19 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$10.76 M |
$21.14 M |
$13.98 M |
$8.71 M |
$8.12 M |
$956,000.00 |
$952,000.00 |
$978,000.00 |
$999,000.00 |
$9.34 M |
| Gross Profit |
-$9.57 M |
-$21.14 M |
-$13.98 M |
-$8.71 M |
-$8.12 M |
-$956,000.00 |
-$952,000.00 |
-$978,000.00 |
-$999,000.00 |
-$9.34 M |
| Gross Profit Ratio |
-8.05 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$344.08 M
|
$294.78 M
|
$259.04 M
|
$201.73 M
|
$166.02 M
|
$99.83 M
|
$71.62 M
|
$28.04 M
|
$15.47 M
|
$2.70 M
|
| General & Administrative
Expenses |
$27.70 M
|
$104.10 M
|
$83.66 M
|
$60.21 M
|
$40.85 M
|
$28.43 M
|
$21.26 M
|
$25.60 M
|
$12.39 M
|
$9.34 M
|
| Selling & Marketing
Expenses |
$79.22 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$106.92 M
|
$104.10 M
|
$83.66 M
|
$60.21 M
|
$40.85 M
|
$28.43 M
|
$21.26 M
|
$25.60 M
|
$12.39 M
|
$9.34 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$450.99 M |
$398.88 M |
$342.70 M |
$261.94 M |
$206.87 M |
$128.26 M |
$92.88 M |
$53.64 M |
$27.86 M |
$12.04 M |
| Cost And Expenses |
$461.75 M |
$398.88 M |
$342.70 M |
$261.94 M |
$206.87 M |
$128.26 M |
$92.88 M |
$53.64 M |
$27.86 M |
$12.04 M |
| Interest Income |
$13.04 M |
$2.99 M |
$451,000.00 |
$2.36 M |
$9.32 M |
$0.00 |
$813,000.00 |
$745,000.00 |
$200,000.00 |
$0.00 |
| Interest Expense |
$0.00 |
$2.99 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$200,000.00 |
$5,660.00 |
| Depreciation &
Amortization |
$33.13 M
|
$21.14 M
|
$13.98 M
|
$8.71 M
|
$8.12 M
|
$956,000.00
|
$952,000.00
|
$978,000.00
|
$999,000.00
|
$88,221.00
|
| EBITDA |
-$427.43 M
|
-$374.76 M
|
-$328.27 M
|
-$250.87 M
|
-$189.43 M
|
-$122.62 M
|
-$91.11 M
|
-$51.92 M
|
-$26.66 M
|
-$11.95 M
|
| EBITDA Ratio |
-359.49 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-387.35
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$13.04 M
|
$2.99 M
|
$451,000.00
|
$2.36 M
|
$9.32 M
|
$4.68 M
|
$813,000.00
|
$745,000.00
|
$200,000.00
|
$5,660.00
|
| Income Before Tax |
-$447.52 M |
-$395.89 M |
-$342.25 M |
-$259.58 M |
-$197.56 M |
-$123.58 M |
-$92.06 M |
-$52.89 M |
-$27.66 M |
-$12.03 M |
| Income Before Tax Ratio
|
-376.38
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$3.48 M |
-$5.97 M |
-$14.43 M |
-$2.36 M |
-$10.49 M |
$4.68 M |
-$952,000.00 |
-$978,000.00 |
-$999,000.00 |
$0.00 |
| Net Income |
-$444.04 M |
-$389.92 M |
-$327.82 M |
-$257.23 M |
-$187.07 M |
-$123.58 M |
-$92.06 M |
-$52.89 M |
-$27.66 M |
-$12.03 M |
| Net Income Ratio |
-373.45 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.89 |
-2.45 |
-2.14 |
-1.86 |
-1.5 |
-1.27 |
-1.41 |
-0.96 |
-0.62 |
-0.48 |
| EPS Diluted |
-1.89 |
-2.45 |
-2.14 |
-1.86 |
-1.5 |
-1.27 |
-1.41 |
-0.96 |
-0.62 |
-0.48 |
| Weighted Average Shares
Out |
$235.13 M
|
$159.26 M
|
$153.41 M
|
$138.30 M
|
$124.34 M
|
$97.28 M
|
$65.24 M
|
$55.27 M
|
$44.41 M
|
$24.99 M
|
| Weighted Average Shares
Out Diluted |
$235.13 M
|
$159.26 M
|
$153.41 M
|
$138.30 M
|
$124.34 M
|
$97.28 M
|
$65.24 M
|
$55.27 M
|
$44.41 M
|
$24.99 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
